DME

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

Boehringer Ingelheim initiates the THULITE study, exploring an oral treatment for diabetic macular edema.

Yesafili is the first biosimilar to Eylea to be approved by Health Canada.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better support patient care.

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, showcasing significant visual acuity improvements.

Matthew Starr, MD, highlights the RHONE-X trial's findings on faricimab, showcasing improved vision and reduced treatment burden for diabetic macular edema patients.

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal disease treatment and reduced injection burden.

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer disease and diabetic macular edema (DME).

Rishi Singh, MD, discusses faricimab's real-world effectiveness in treating diabetic macular edema, highlighting improved vision and reduced treatment frequency.

Carl D. Regillo, MD, shares insights on the VERONA trial of EYP-1901 at the Retina World Congress 2025 meeting held in Fort Lauderdale, Florida.

Optigo Biotherapeutics presents promising preclinical data at ARVO.

Innovent Biologics initiates phase 2 trial for efdamrofusp alfa, a promising treatment for diabetic macular edema, aiming to improve patient outcomes.

Isarna Therapeutics reveals promising Phase 2 BETTER trial results for ISTH0036, a potential breakthrough in treating retinal fibrosis.

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority to aflibercept and strong safety profile.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative diseases and retinal conditions.

Brazilian researchers reveal how choroidal thickness influences treatment response in diabetic macular edema, enhancing personalized therapy strategies.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope for innovative retinal therapies.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The annual ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Results showed an unequal distributions of these clinical trials among rural and low-income populations.